Publikationen

Baumann K-S, Derksen L, Witt M, Adeberg S, Zink K. The influence of different versions of FLUKA and GEANT4 on the calculation of response functions of ionization chambers in clinical proton beams. Phys Med Biol. 2023 Dec 68(24):24NT01. doi:10.1088/1361-6560/ad0ad4. PMID: 37939402.

Lautenschlaeger S, Dumke C, Exeli L, Hauswald H, Engenhart-Cabillic R, Eberle F. Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy. Strahlenther Onkol. 2023 Nov 199(11):982–991. doi:10.1007/s00066-023-02106-5. PMID: 37428207.

Gkika E, Kostyszyn D, Fechter T, Moustakis C, Ernst F, Boda-Heggemann J, Sarria G, Dieckmann K, Dobiasch S, Duma MN, Eberle F, Kroeger K, Häussler B, Izaguirre V, Jazmati D, Lautenschläger S, u. a. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Strahlenther Onkol. 2023 Nov 199(11):973–981. doi:10.1007/s00066-023-02085-7. PMID: 37268767.

Alissa M, Zink K, Czarnecki D. Investigation of Monte Carlo simulations of the electron transport in external magnetic fields using Fano cavity test. Z Med Phys. 2023 Nov 33(4):499–510. doi:10.1016/j.zemedi.2022.07.002. PMID: 36030166.

Rossi G, Failing T, Gainey M, Kollefrath M, Hensley F, Zink K, Baltas D. Determination of the dose rate around a HDR 192Ir brachytherapy source with the microDiamond and the microSilicon detector. Z Med Phys. 2023 Nov 33(4):463–478. doi:10.1016/j.zemedi.2022.07.004. PMID: 36038432.

Ahern V, Adeberg S, Fossati P, Garrett R, Hoppe B, Mahajan A, Orlandi E, Orecchia R, Prokopovich D, Seuntjens J, u. a. An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia. Radiother Oncol. 2023 Oct 187(109816):109816. doi:10.1016/j.radonc.2023.109816. PMID: 37480996

Baumann K-S, Gomà C, Wulff J, Kretschmer J, Zink K. Monte Carlo calculated ionization chamber correction factors in clinical proton beams – deriving uncertainties from published data. Phys Med. 2023 Sep 113(102655):102655. doi:10.1016/j.ejmp.2023.102655. PMID: 37603909

Burg JM, Flatten V, Wulff J, Timmermann B, Vorwerk H, Zink K. Induced luminescence in water and PMMA - spectral analysis for irradiations with proton beams within the clinical energy range. Biomed Phys Eng Express. 2023 Jul 9(5):057001. doi:10.1088/2057-1976/ace6a2. PMID: 37437552.

Fink CA, Weykamp F, Adeberg S, Bozorgmehr F, Christopoulos P, Lang K, König L, Hörner-Rieber J, Thomas M, Steins M, u. a. Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy. Clin Transl Radiat Oncol. 2023 Jul 42(100665):100665. doi:10.1016/j.ctro.2023.100665. PMID: 37564923.

Alissa M, Zink K, Kapsch R-P, Schoenfeld AA, Frick S, Czarnecki D. Experimental and Monte Carlo‐based determination of magnetic field correction factors kB,Qk_B,Q in high‐energy photon fields for two ionization chambers. Med Phys. 2023 Jul 50(7):4578–4589. doi:10.1002/mp.16345. PMID: 36897832

Derksen L, Flatten V, Engenhart-Cabillic R, Zink K, Baumann K-S. A method to implement inter-track interactions in Monte Carlo simulations with TOPAS-nBio and their influence on simulated radical yields following water radiolysis. Phys Med Biol. 2023 Jun 68(13):135017. doi:10.1088/1361-6560/acdc7d. PMID: 37285861.

Wächter S, Roth S, Gercke N, Schötz U, Dikomey E, Engenhart-Cabillic R, Maurer E, Bartsch D, Di Fazio P. Anti-proliferative effect of radiotherapy and implication of immunotherapy in anaplastic thyroid cancer cells. Life (Basel). 2023 Jun 13(6):1397. doi:10.3390/life13061397. PMID: 37374179.

Charuchinda W, Horst F, Simeonov Y, Schuy C, Penchev P, Poulsen P, Sitarz M, Busold S, Reidel C-A, Folkerts M, …, Zink K, u. a. 3D range-modulators for proton therapy: near field simulations with FLUKA and comparison with film measurements. J Phys Conf Ser. 2023 Jun 2431(1):012081. doi:10.1088/1742-6596/2431/1/012081.

Oertel M, Hering D, Nacke N, Kittel C, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhart-Cabillic R, u. a. Radiation therapy in the German Hodgkin study group HD 16 and HD 17 trials: Quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era. Adv Radiat Oncol. 2023 May-Jun 8(3):101169. doi:10.1016/j.adro.2022.101169. PMID: 36896214.

Oertel M, Hering D, Baues C, Kittel C, Fuchs M, Kriz J, Kröger K, Vordermark D, Herfarth K, Engenhart-Cabillic R, u. a. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial. Front Oncol. 2023 May 13. doi:10.3389/fonc.2023.1183906. PMID: 37213291.

Czarnecki D, Zink K, Alissa M, Flatten V, Espelage T, Schoenfeld AA. Validation of an EGSnrc‐based Monte Carlo model for a complex 2D‐array for technical QA measurements of a linear accelerator. Med Phys. 2023 Apr 50(4):2552–2559. doi:10.1002/mp.16205. PMID: 36604950.

Roers J, Czarnecki D, Alissa M, Zink K. Spectral analysis of Monte Carlo calculated fluence correction and cema conversion factors for high-energy photon beams at different depths. Front Phys. 2023 Jan 10. doi:10.3389/fphy.2022.1075514. dx.doi.org/10.3389/fphy.2022.1075514.

Baack L, Schuy C, Brons S, Horst F, Voss B, Zink K, Haberer T, Durante M, Weber U. Reduction of recombination effects in large plane parallel beam monitors for FLASH radiotherapy with scanned ion beams. Phys Med. Dec 2022 104:136–144. doi:10.1016/j.ejmp.2022.10.029. PMID: 36403543.

Schade S, Engenhart-Cabillic R, Zink K, Czarnecki D. The fast calibration model for dosimetry with an electronic portal imaging device. J Appl Clin Med Phys. Nov 2022 23(11). doi:10.1002/acm2.13599. PMID: 35876832.

Failing T, Hartmann GH, Hensley FW, Keil B, Zink K. Enhancement of the EGSnrc code egs_chamber for fast fluence calculations of charged particles. Z Med Phys. Nov 2022 32(4):417–427. doi:10.1016/j.zemedi.2022.04.003. PMID: 35643800.

Dumke R, Dumke C, Eberle F, Nimsky C, Keber U, Engenhart-Cabillic R, Lautenschläger S. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy. Strahlenther Onkol. 2022 Oct 198(10):892–906. doi:10.1007/s00066-022-01959-6. PMID: 35612598.

Rogers S, Baumert B, Blanck O, Böhmer D, Boström J, Engenhart-Cabillic R, Ermis E, Exner S, Guckenberger M, Habermehl D, u. a. Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO). Strahlenther Onkol. 2022 Oct 198(10):919–925. doi:10.1007/s00066-022-01991-6. PMID: 36006436.

Foote RL, Tsujii H, Imai R, Tsuji H, Hug EB, Kanai T, Lu JJ, Debus J, Engenhart-Cabillic R, Mahajan A. The majority of United States citizens with cancer do not have access to carbon ion radiotherapy. Front Oncol. 2022 Jul 12. doi:10.3389/fonc.2022.954747. PMID: 35875126.

Subtil FSB, Gröbner C, Recknagel N, Parplys AC, Kohl S, Arenz A, Eberle F, Dikomey E, Engenhart-Cabillic R, Schötz U. Dual PI3K/mTOR inhibitor NVP-BEZ235 leads to a synergistic enhancement of cisplatin and radiation in both HPV-negative and -positive HNSCC cell lines. Cancers (Basel). 2022 Jun 14(13):3160. doi:10.3390/cancers14133160. PMID: 35804930.

Lautenschlaeger FS, Dumke R, Schymalla M, Hauswald H, Carl B, Stein M, Keber U, Jensen A, Engenhart-Cabillic R, Eberle F. Comparison of carbon ion and photon reirradiation for recurrent glioblastoma. Strahlenther Onkol. 2022 May 198(5):427–435. doi:10.1007/s00066-021-01844-8. PMID: 34523017.

Simeonov Y, Weber U, Schuy C, Engenhart-Cabillic R, Penchev P, Flatten V, Zink K. Development, Monte Carlo simulations and experimental evaluation of a 3D range-modulator for a complex target in scanned proton therapy. Biomed Phys Eng Express. 2022 Mar 8(3):035006. doi:10.1088/2057-1976/ac5937. PMID: 35226887.

Tiwari DK, Hannen R, Unger K, Kohl S, Heß J, Lauber K, Subtil FSB, Dikomey E, Engenhart-Cabillic R, Schötz U. IL1 pathway in HPV-negative HNSCC cells is an indicator of radioresistance after photon and carbon ion irradiation without functional involvement. Front Oncol. 2022 Apr 12. doi:10.3389/fonc.2022.878675. PMID: 35530351.

Eberle F, Engenhart-Cabillic R, Schymalla MM, Dumke C, Schötz U, Subtil FSB, Baumann K-S, Stuck BA, Langer C, Jensen AD, Hauswald H, Lautenschläger S. Carbon ion beam boost irradiation in malignant tumors of the nasal vestibule and the anterior nasal cavity as an organ-preserving therapy. Front Oncol. 2022 Feb 12. doi:10.3389/fonc.2022.814082. PMID: 35242709.

Tambas M, van der Laan HP, Steenbakkers RJHM, Doyen J, Timmermann B, Orlandi E, Hoyer M, Haustermans K, Georg P, Burnet NG, …, Eberle F, u. a. 2022. Current practice in proton therapy delivery in adult cancer patients across Europe. Radiother Oncol. 2022 Feb 167:7–13. doi:10.1016/j.radonc.2021.12.004. PMID: 34902370.

Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, …, Vorwerk H, u.a. 2022a. S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome: Kurzversion 2.00 - Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol. 2022a Feb 60(02):219–238. doi:10.1055/a-1589-7638. PMID: 35042249

Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, …, Vorwerk H, u. a. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome: Langversion 2.0 - Juni 2021 - AWMF-Registernummer: 032-053OL. Z Gastroenterol. 2022b Feb 60(02):e186–e227. doi:10.1055/a-1589-7854. PMID: 35148560.

Alissa M, Zink K, Tessier F, Schoenfeld AA, Czarnecki D. Monte Carlo calculated beam quality correction factors for two cylindrical ionization chambers in photon beams. Phys Med. 2022 Feb 94:17–23. doi:10.1016/j.ejmp.2021.12.012. PMID: 34972070.

Vorwerk H, Engenhart-Cabillic R. Students’ learning behavior in digital education for radiation oncology. Strahlenther Onkol. 2022 Jan 198(1):12–24. doi:10.1007/s00066-021-01858-2. PMID: 34842943.

Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, …, Engenhart-Cabillic R, …, Vorwerk H, u. a. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2022 Jan 198(1):1–11. doi:10.1007/s00066-021-01861-7. PMID: 34786605.

Burg JM, Flatten V, Witt M, Derksen L, Weber U, Engenhart-Cabillic R, Vorwerk H, Experimental determination of modulation power of lung tissue for particle therapy. Phys Med Biol. 2021 Dec 66(24):245018. doi:10.1088/1361-6560/ac3e0d. PMID: 34844221.

König L, Jäkel C, von Knebel Doeberitz N, Kieser M, Eberle F, Münter M, Debus J, Herfarth K. Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy—GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study. Radiat Oncol. 2021 Dec 16(1). doi:10.1186/s13014-021-01962-8. PMID: 34930368.

Paz AES, Baumann K-S, Weber UA, Witt M, Zink K, Durante M, Graeff C. Compensating for beam modulation due to microscopic lung heterogeneities in carbon ion therapy treatment planning. Med Phys. 2021 Dec 48(12):8052–8061. doi:10.1002/mp.15292. PMID: 34668589.

Hartmann GH, Andreo P, Kapsch R-P, Zink K. Cema‐based formalism for the determination of absorbed dose for high‐energy photon beams. Med Phys. 2021 Nov 48(11):7461–7475. doi:10.1002/mp.15266. PMID: 34613620.

Flatten V, Burg J, Witt M, Derksen L, Fragoso Costa P, Wulff J, Bäumer C, Timmermann B, Weber U, Vorwerk H, Engenhart-Cabillic R, Zink K, Baumann K-S.   Estimating the modulating effect of lung tissue in particle therapy using a clinical CT voxel histogram analysis. Phys Med Biol. 2021 Sep 66(18):185002. doi:10.1088/1361-6560/ac176e. PMID: 34298533.

Baumann K-S, Derksen L, Witt M, Michael Burg J, Engenhart-Cabillic R, Zink K. Monte Carlo calculation of beam quality correction factors in proton beams using FLUKA. Phys Med Biol. 2021 Aug 66(17):17NT01. doi:10.1088/1361-6560/ac1c4b. PMID: 34378546.

Derksen L, Pfuhl T, Engenhart-Cabillic R, Zink K, Baumann K-S. Investigating the feasibility of TOPAS-nBio for Monte Carlo track structure simulations by adapting GEANT4-DNA examples application. Phys Med Biol. 2021 Aug 66(17):175023. doi:10.1088/1361-6560/ac1d21. PMID: 34384060.

Schäfer N, Bumes E, Eberle F, Fox V, Gessler F, Giordano FA, Konczalla J, Onken J, Ottenhausen M, Scherer M, u. a. Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. J Neurooncol. 2021 Jul 153(3):479–485. doi:10.1007/s11060-021-03784-w. PMID: 34115248.

Baumann K-S, Kaupa S, Bach C, Engenhart-Cabillic R, Zink K. Monte Carlo calculation of perturbation correction factors for air-filled ionization chambers in clinical proton beams using TOPAS/GEANT. Z Med Phys. 2021 May 31(2):175–191. doi:10.1016/j.zemedi.2020.08.004. PMID: 33775521.

Simeonov Y, Weber U, Schuy C, Engenhart-Cabillic R, Penchev P, Durante M, Zink K. Monte Carlo simulations and dose measurements of 2D range-modulators for scanned particle therapy. Z Med Phys. 2021 May 31(2):203–214. doi:10.1016/j.zemedi.2020.06.008. PMID: 32711939.

Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, u. a. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer. 2021 May 68(S2). doi:10.1002/pbc.28562. PMID: 33818890.

Andreo P, Burns DT, Kapsch RP, McEwen M, Vatnitsky S, Andersen CE, Ballester F, Borbinha J, Delaunay F, Francescon P, Hanlon MD, Mirzakhanian L, Muir B, Ojala J, Oliver CP, Pimpinella M, Pinto M, de Prez LA, Seuntjens J, Sommier L, Teles P, Tikkanen J, Vijande J, Zink K. Determination of consensus k _Q values for megavoltage photon beams for the update of IAEA TRS-398. Phys Med Biol. 2020 May 7;65(9):095011. doi: 10.1088/1361-6560/ab807b. PMID: 32182598.

Baumann KS, Kaupa S, Bach C, Engenhart-Cabillic R, Zink K. Monte Carlo calculation of beam quality correction factors in proton beams using TOPAS/GEANT4. Phys Med Biol. 2020 Mar 6;65(5):055015. doi: 10.1088/1361-6560/ab6e53. PMID: 31962306.

Baumann KS, Flatten V, Weber U, Lautenschläger S, Eberle F, Zink K, Engenhart-Cabillic R. Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients. Radiat Oncol. 2020 Feb 3;15(1):29. doi: 10.1186/s13014-020-1475-x. Erratum for: Radiat Oncol. 2019 Oct 25;14(1):183. PMID: 32014028; PMCID: PMC6996163.

Burg JM, Horst F, Wulff J, Timmermann B, Vorwerk H, Zink K. Optical range determination of clinical proton beams in water. A comparison with standard measurement methods. Phys Med. 2020 May;73:197-203. doi: 10.1016/j.ejmp.2020.03.012. Epub 2020 May 4. PMID: 32380438.

Eberle F, Lautenschläger S, Engenhart-Cabillic R, Jensen AD, Carl B, Stein M, Debus J, Hauswald H. Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma. Cancer Manag Res. 2020 Jan 28;12:633-639. doi: 10.2147/CMAR.S217824. PMID: 32095084; PMCID: PMC6995286.

Flatten V, Friedrich A, Engenhart-Cabillic R, Zink K. A phantom based evaluation of the dose prediction and effects in treatment plans, when calculating on a direct density CT reconstruction. J Appl Clin Med Phys. 2020 Mar;21(3):52-61. doi: 10.1002/acm2.12824. PMID: 32176455; PMCID: PMC7075385.

Degenhardt S, Dreffke K, Schötz U, Petersen C, Engenhart-Cabillic R, Rothkamm K, Dahm-Daphi J, Dikomey E, Mansour WY. Establishment of a Transformation Coupled in vitro End Joining Assay to Estimate Radiosensitivity in Tumor Cells. Front Oncol. 2020 Aug 20;10:1480. doi: 10.3389/fonc.2020.01480. PMID: 32974177; PMCID: PMC7468517.

Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S, Moustakis C. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol. 2020 May;196(5):417-420. doi: 10.1007/s00066-020-01603-1. PMID: 32211940; PMCID: PMC7182610.

Hartmann GH, Hensley F, Kapsch RP, Poppe B, Sauer O, Würfel J, Zink K. Ermittlung der Wasser-Energiedosis nach der Sondenmethode gemäß DIN 6800 Teil 1: Vorschlag für eine Erweiterung der Grundgleichung [Detector Based Determination of Water Absorbed Dose According to DIN 6800 Teil 1: Suggestion for an Extension of the Fundamental Formalism]. Z Med Phys. 2020 Feb;30(1):24-39. German. doi: 10.1016/j.zemedi.2019.05.001. Epub 2019 Oct 2. PMID: 31585786.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Dieckmann K, Eich HT, Flentje M, Grills I, Eble M, Hope A, Grosu AL, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Guckenberger M. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2020 Jan;142:210-216. doi: 10.1016/j.radonc.2019.07.008. Epub 2019 Aug 17. PMID: 31431371.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Blanck O, Dieckmann K, Eich HT, Mantel F, Eble M, Hope A, Grosu AL, Nevinny-Stickel M, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Grills I, Guckenberger M. Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):579-586. doi: 10.1016/j.ijrobp.2020.03.005. Epub 2020 Mar 15. PMID: 32188579.

Lerch S, Berthold S, Ziemann F, Dreffke K, Subtil FSB, Senger Y, Jensen A, Engenhart-Cabillic R, Dikomey E, Wittig A, Eberle F, Schötz U. HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation. Radiother Oncol. 2020 Jul 24;151:134-140. doi:10.1016/j.radonc.2020.07.032. Epub ahead of print. PMID: 32717362.

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol. 2020 May 1;23:43-49. doi:10.1016/j.ctro.2020.04.010. PMID: 32420463; PMCID: PMC7218223.

Schötz U, Balzer V, Brandt FW, Ziemann F, Subtil FSB, Rieckmann T, Köcher S, Engenhart-Cabillic R, Dikomey E, Wittig A, Arenz A. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining. Cancers (Basel). 2020 Feb 18;12(2):467. doi:10.3390/cancers12020467. PMID: 32085396; PMCID: PMC7072694.

Sieron HL, Eberle F, Gress TM, Mahnken AH, Wiegand S. Safety of Prophylactic Gastrostomy Tube Placement and Gastrostomy Tube Usage in Patients Treated by Radio(chemo)therapy for Head and Neck Cancer. Anticancer Res. 2020 Feb;40(2):1167-1173. doi:10.21873/anticanres.14059. PMID: 32014970.

Stein M, Dohmen H, Wölk B, Eberle F, Kolodziej M, Acker T, Uhl E, Jensen A. Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields. Front Oncol. 2020 Apr 21;10:477. doi:10.3389/fonc.2020.00477. PMID: 32373516; PMCID: PMC7186451.

Tikkanen J, Zink K, Pimpinella M, Teles P, Borbinha J, Ojala J, Siiskonen T, Gomà C, Pinto M. Calculated beam quality correction factors for ionization chambers in MV photon beams. Phys Med Biol. 2020 Mar 26;65(7):075003. doi:10.1088/1361-6560/ab7107. PMID: 31995531.

Schröder C, Engenhart-Cabillic R, Kirschner S, Blank E, Buchali A. Changes of lung parenchyma density following high dose radiation therapy for thoracic carcinomas – an automated analysis of follow up CT scans. Radiat Oncol. 2019 14(1). doi:10.1186/s13014-019-1276-2. PMID: 31036015.

Baumann KS, Flatten V, Weber U, Lautenschläger S, Eberle F, Zink K, Engenhart-Cabillic R. Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients. Radiat Oncol. 2020 Feb 3;15(1):29. doi: 10.1186/s13014-020-1475-x. Erratum for: Radiat Oncol. 2019 Oct 25;14(1):183. PMID: 32014028.

Seltzsam S, Ziemann F, Dreffke K, Preising S, Arenz A, Schötz U, Engenhart-Cabillic R, Dikomey E, Wittig A. In HPV-positive HNSCC cells, functional restoration of the p53/p21 pathway by proteasome inhibitor bortezomib does not affect radio- or chemosensitivity. Transl Oncol. 2019 12(3):417–425. doi:10.1016/j.tranon.2018.11.013. PMID: 30554133.

Lautenschlaeger S, Iancu G, Flatten V, Baumann K, Thiemer M, Dumke C, Zink K, Hauswald H, Vordermark D, Mauz-Körholz C, Engenhart-Cabillic R, Eberle F. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease. Radiat Oncol. 2019 14(1). doi:10.1186/s13014-019-1360-7. PMID: 31477141.

Baumann K-S, Horst F, Zink K, Gomà C. Comparison of penh, fluka, and Geant4/topas for absorbed dose calculations in air cavities representing ionization chambers in high‐energy photon and proton beams. Med Phys. 2019 46(10):4639–4653. PMID: 31350915

Hartmann GH, Zink K. A Monte Carlo study on the PTW 60019 microDiamond detector. Med Phys. 2019 46(11):5159–5172. doi:10.1002/mp.13721. PMID: 31314919

Flatten V, Baumann K-S, Weber U, Engenhart-Cabillic R, Zink K. Quantification of the dependencies of the Bragg peak degradation due to lung tissue in proton therapy on a CT-based lung tumor phantom. Phys Med Biol. 2019 64(15):155005. doi:10.1088/1361-6560/ab2611. PMID: 31151126.

Howitz S, Wiezorek T, Wittig A, Vorwerk H, Zink K. Fluence-weighted average subfield size in helical TomoTherapy. Z Med Phys. 2019 29(4):337–348. doi:10.1016/j.zemedi.2019.03.003.

Fels J, Pigorsch S, Vorwerk H, Engenhart-Cabillic R, van Oorschot B. Palliative care in everyday practice of radiation oncologists : Results from a web-based survey among medical members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2019 Jul;195(7):659-667. doi:10.1007/s00066-018-1403-2. PMID: 30498845

Arenz A, Patze J, Kornmann E, Wilhelm J, Ziemann F, Wagner S, Wittig A, Schoetz U, Engenhart-Cabillic R, Dikomey E, Fritz B. HPV-negative and HPV-positive HNSCC cell lines show similar numerical but different structural chromosomal aberrations. Head Neck. 2019 Nov;41(11):3869-3879. doi:10.1002/hed.25924. PMID: 31441163

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective. Front Oncol. 2019 May 10;9:318. doi:10.3389/fonc.2019.00318. PMID: 31134146.

Jensen AD, Debus J. Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck. Radiat Oncol. 2019 Nov 6;14(1):194. doi:10.1186/s13014-019-1395-9. PMID: 31694720.

Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol. 2019 11(5):367–376. doi:10.4251/wjgo.v11.i5.367. PMID: 31139307.

Ringbæk TP, Weber U, Santiago A, Iancu G, Wittig A, Grzanka L, Bassler N, Engenhart-Cabillic R, Zink K. Validation of new 2D ripple filters in proton treatments of spherical geometries and non-small cell lung carcinoma cases. Phys Med Biol. 2018 63(24):245020. doi:10.1088/1361-6560/aaede9. PMID: 30523868. 

Gökyildirim MY, Grandel U, Hattar K, Dahlem G, Schuetz E, Leinberger FH, Eberle F, Sibelius U, Grimminger F, Seeger W, Engenhart-Cabillic R, Dikomey E, Subtil FSB. Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget 2018 9(48):28976-2898810.18632. doi:10.18632/oncotarget.25665. PMID: 29989005.

Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H,Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T,Stelljes M, Bornhäuser M. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol 2018 5(4):e161-e169 1016/S2352-3026(18)30022-X. doi:10.1016/S2352-3026(18)30022-X. PMID: 29550384.

Caldwell RB, Braselmann H, Heuer S, Schötz U, Zitzelsberger H. Gain‐of‐function analysis of cis‐acting diversification elements in DT40 cells. Immunol Cell Biol. 2018 96(9):948–957. doi:10.1111/imcb.12158. PMID: 29665088.

Linge A, Schötz U, Löck S, Lohaus F, von Neubeck C, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol. 2018 127(1):27-35. doi:10.1016/j.radonc.2017.12.007. PMID: 29295747.

Krombach J, Hennel R, Brix N, Orth M, Schötz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, Sperandio M, Vogl T, Unkel S, Belka C, Lauber K. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncolmmunology. 2018
8(1):e1523097. doi:10.1080/2162402X. PMID: 30546963.

Hartmann GH, Zink K. Decomposition of the dose conversion factor based on fluence spectra of secondary charged particles: Application to lateral dose profiles in photon fields. Med Phys. 2018 45(9):4246–4256. doi:10.1002/mp.13081. PMID: 29974479.

Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, Krombach G, Blau W, Grimminger F, Seeger W, Klussmann JP, Bräuninger A, Gattenlöhner. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head Neck. 2018 40(6):1109-1119. doi:10.1002/hed.25041. PMID: 29522268.

Ziemann F, Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil FSB, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A. Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. Oncotarget. 2017 8(62):105170–105183. doi:10.18632/oncotarget.22005. PMID: 29285242.

Baumann K-S, Witt M, Weber U, Engenhart-Cabillic R, Zink K. An efficient method to predict and include Bragg curve degradation due to lung-equivalent materials in Monte Carlo codes by applying a density modulation. Phys Med Biol. 2017 62(10):3997–4016. doi:10.1088/1361-6560/aa641f. PMID: 28252449.

Printz Ringbæk T, Simeonov Y, Witt M, Engenhart-Cabillic R, Kraft G, Zink K, Weber U. Modulation power of porous materials and usage as ripple filter in particle therapy. Phys Med Biol. 2017 62(7):2892–2909. doi:10.1088/1361-6560/aa5c28. PMID: 28140381.

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A. Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy. Strahlenther Onkol. 2017 193(2):125–131. doi:10.1007/s00066-016-1067-8. PMID: 27783103

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A. Patient’s quality of life after high-dose radiation therapy for thoracic carcinomas: Changes over time and influence on clinical outcome. Strahlenther Onkol. 2017 193(2):132–140. doi:10.1007/s00066-016-1068-7. PMID: 27787567.

Horst F, Schuy C, Weber U, Brinkmann K-T, Zink K. Measurement of charge- and mass-changing cross sections for He4+C12 collisions in the energy range 80–220 MeV/u for applications in ion beam therapy. Phys Rev C. 2017 96(2). doi:10.1103/physrevc.96.024624.

Czarnecki D, Poppe B, Zink K. Monte Carlo-based investigations on the impact of removing the flattening filter on beam quality specifiers for photon beam dosimetry. Med Phys. 2017 44(6):2569–2580. doi:10.1002/mp.12252. PMID: 28369978

Horst F, Fehrenbacher G, Zink K. On the neutron radiation field and air activation around a medical electron linac. Radiat Prot Dosimetry. 2017 174(2). doi:10.1093/rpd/ncw120. PMID: 27170731

Hattar K, Reinert CP, Sibelius U, Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger F, Seeger W, u. a. Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunol Immunother. 2017 66(6):799–809. doi:10.1007/s00262-017-1980-4. PMID: 28314957.

Simeonov Y, Weber U, Penchev P, Printz Ringbæk T, Schuy Ch, Brons S, Engenhart-Cabillic R, Bliedtner J, Zink K. 3D range-modulator for scanned particle therapy: development, Monte Carlo simulations and experimental evaluation. Phys. Med. Biol. 2017 62: 7075-7096. doi:10.1088/1361-6560/aa81f4. PMID: 28741595.

von Voigts-Rhetz P, Vorwerk H, Zink K. On the Perturbation Correction Factor pcav of the Markus Parallel-Plate Ion Chamber in Clinical Electron Beams. Int. J. Med. Phys. Clin.Eng. Rad. Oncol. 2017 6: 150-161.

Hoch S, Thelen K, Vorwerk H, Netzer C, Wilhelm T, Günzel T, Teymoortash A. Impact of Different Treatment Concepts on Regional Failure in Advanced Oropharyngeal Cancer. Anticancer Res. 2017 Feb;37(2):727-734. doi:10.21873/anticanres.11370. PMID: 28179323.

Wagner DM, Hüttenrauch P, Anton M, von Voigts-Rhetz P, Zink K, Wolff HA. Feasibility study of entrance and exit dose measurements at the contra lateral breast with alanine/electron spin resonance dosimetry in volumetric modulated radiotherapy of breast cancer. Phys Med Biol. 2017 Jul 7;6e2(13):5462-5472. doi:10.1088/1361-6560/aa6ee2. PMID: 28436921.

Kuhnt T, Schreiber A, Pirnasch A, Hautmann MG, Hass P, Sieker FP, Engenhart-Cabillic R, Richter M, Dellas K, Dunst J. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study. Strahlenther Onkol. 2017 Sep;193(9):733-741. doi:10.1007/s00066-017-1145-6. PMID: 28500491.

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfarth K, Lukas P. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group. Strahlenther Onkol. 2017 Feb;193(2):100-108. doi:10.1007/s00066-016-1048-y. PMID: 27678010.

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfart K, Lukas P, Plütschow A, Schmidberger H, Marnitz-Schulze S, Fuchs M, Engert A, Eich HAT. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials: Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2017 Feb;193(2):109-115. doi:10.1007/s00066-016-1036-2. PMID: 27596217.

Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, …, Wittig A, u. a. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017 123(2):182–188. doi:10.1016/j.radonc.2017.01.003. PMID: 28169042.

Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520 doi:10.1016/j.ijrobp.2016.09.026. PMID: 27843031.

Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic R, Hänze J, Hattar K, Dikomey E, Subtil FSB. In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clin Transl Radiat Oncol. 2017 2:69–75. doi:10.1016/j.ctro.2017.02.001. PMID: 29658004.

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A. Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy. Strahlenther Onkol. 2017 193(2):125–131. doi:10.1007/s00066-016-1067-8. PMID: 27783103

Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017 May;123(2):182-188. doi:10.1016/j.radonc.2017.01.003. PMID: 28169042.

Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520. doi:10.1016/j.ijrobp.2016.09.026. PMID: 27843031.

Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic R, Hänze J, Hattar K, Dikomey E, Subtil FS. In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clin Trans Radiat Oncol. 2017 2:69-75. doi:10.1016/j.ctro.2017.02.001. PMID: 29658004.

Wagner DM, Hüttenrauch P, Anton M, von Voigts-Rhetz P, Zink K, Wolff HA. Feasibility study of entrance and exit dose measurements at the contra lateral breast with alanine/electron spin resonance dosimetry in volumetric modulated radiotherapy of breast cancer. Phys Med Biol. 2017 Jul 7;62(13):5462-5472. doi:10.1088/1361-6560/aa6ee2. PMID: 28436921.

Simeonov Y, Weber U, Penchev P, Ringbæk TP, Schuy C, Brons S, Engenhart-Cabillic R, Bliedtner J, Zink K. 3D range-modulator for scanned particle therapy: development, Monte Carlo simulations and experimental evaluation. Phys Med Biol. 2017 Aug 11;62(17):7075-7096. doi:10.1088/1361-6560/aa81f4. PMID: 28741595.

Hattar K, Reinert CP, Sibelius U, Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger F, Seeger W, Grandel U. Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunol Immunother. 2017 Jun;66(6):799-809. doi:10.1007/s00262-017-1980-4. PMID: 28314957.

Czarnecki D, Poppe B, Zink K. Monte Carlo-based investigations on the impact of removing the flattening filter on beam quality specifiers for photon beam dosimetry. Med Phys. 2017 Jun;44(6):2569-2580. doi:10.1002/mp.12252. PMID: 28369978.

Kuhnt T, Schreiber A, Pirnasch A, Hautmann MG, Hass P, Sieker FP, Engenhart-Cabillic R, Richter M, Dellas K, Dunst J. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2017 May 12. doi: 10.1007/s00066-017-1145-6. PMID: 28500491.

Horst F, Fehrenbacher G, Zink K. On the neutron radiation field and air activation around a medical electron linac. Radiat Prot Dosimetry. 2017 Apr 25;174(2):147-158. doi:10.1093/rpd/ncw120. PMID: 27170731.

Baumann KS, Witt M, Weber U, Engenhart-Cabillic R, Zink K. An efficient method to predict and include Bragg curve degradation due to lung-equivalent materials in Monte Carlo codes by applying a density modulation. Phys Med Biol. 2017 Mar 21;62(10):3997-4016. doi:10.1088/1361-6560/aa641f. PMID: 28252449.

Toke Printz Ringbæk, Yuri Simeonov, Matthias Witt, Rita Engenhart-Cabillic, Gerhard Kraft, Klemens Zink, Uli Weber. Modulation power of porous materials and usage as ripple filter in particle therapy. Phys Med Biol. 2017 Apr 7;62(7):2892-2909. doi:10.1088/1361-6560/aa5c28. PMID: 28140381.

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfart K, Lukas P, Plütschow A, Schmidberger H, Staar S, Fuchs M, Engert A, Eich HAT. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2017 Feb;193(2):109-115. doi:10.1007/s00066-016-1036-2. PMID: 27596217.

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A. Patient's quality of life after high-dose radiation therapy for thoracic carcinomas : Changes over time and influence on clinical outcome. Strahlenther Onkol. 2017 Feb;193(2):132-140. doi:10.1007/s00066-016-1068-7. PMID: 27787567.

Horst F, Schuy Ch, Weber U, Brinkmann K-T, Zink K. Measurement of charge- and mass-changing cross sections for 4He + 12C collisions in the energy range 80 - 220 MeV/u for applications in ion beam therapy. Phys. Rev. C 2016 96: 024624-1 - 024624-11.

Ziemann F; Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil FSB, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A. Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. Oncotarget 2016 8(62):105170-105183. doi:10.18632/oncotarget.22005. PMID: 29285242.

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfarth K, Lukas P, Schmidberger H, Marnitz-Schulze S, Fuchs M, Engert A, Eich HAT. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group. Strahlenther Onkol. 2017 Feb;193(2):100-108. doi:10.1007/s00066-016-1048-y. PMID: 27678010.

Eekers DB, Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F, Ahn PH, Janssens GO, Hoebers FJ, Friedmann T, Solberg T, Walsh S, Troost EG, Kaanders JH, Lambin P. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016 Dec;121(3):387-394. doi:10.1016/j.radonc.2016.08.020. PMID: 27639891.

von Voigts-Rhetz P, Anton M, Vorwerk H, Zink K. Perturbation correction for alanine dosimeters in different phantom materials in high-energy photon beams. Phys Med Biol. 2016 Feb 7;61(3):N70-9. doi:10.1088/0031-9155/61/3/N70. PMID: 26758810.

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A. A lot to a little or a little to a lot-which dose-volume relationship ensures the best clinical outcome in the high dose radiation therapy of thoracic tumors? A prospective approach. J Thorac Dis. 2016 Aug;8(8):2053-60. doi:10.21037/jtd.2016.07.92. PMID: 27621859

Eberle F, Saulich MF, Leinberger FH, Seeger W, Engenhart-Cabillic R, Dikomey E, Hänze J, Hattar K, Subtil FS. Cancer cell motility is affected through 3D cell culturing and SCF/c-Kit pathway but not by X-irradiation. Radiother Oncol. 2016 Jun;119(3):537-43. doi:10.1016/j.radonc.2016.04.036. PMID: 27178146.

Ringbæk TP, Weber U, Santiago A, Simeonov Y, Fritz P, Krämer M, Wittig A, Bassler N, Engenhart-Cabillic R, Zink K. Dosimetric comparisons of carbon ion treatment plans for 1D and 2D ripple filters with variable thicknesses. Phys Med Biol. 2016 Jun 7;61(11):4327-41. doi:10.1088/0031-9155/61/11/4327. PMID: 27203127

Santiago A, Barczyk S, Jelen U, Engenhart-Cabillic R, Wittig A. Challenges in radiobiological modeling: Can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data? Radiat Oncol. 2016 May 6;11(1):67. doi:10.1186/s13014-016-0643-5. PMID: 27154064.

Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S, Schade-Brittinger C, Hoeffken H, Engenhart-Cabillic R, Brugger M, Strauch K. Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial. PLoS One. 2016 Mar 18;11(3):e0151316. doi:10.1371/journal.pone.0151316. PMID: 26991494.

Santiago A, Fritz P, Mühlnickel W, Engenhart-Cabillic R, Wittig A. Changes in the radiological depth correlate with dosimetric deterioration in particle therapy for stage I NSCLC patients under high frequency jet ventilation. Acta Oncol. 2015;54(9):1631-7. doi:10.3109/0284186X.2015.1067716. PMID: 26228661.

Horst F, Fehrenbacher G, Radon T, Kozlova E, Rosmej O, Czarnezki D, Schrenk O, Breckow J, Zink K. A TLD-based ten channel system for the spectrometry of bremsstrahlung generated by laser-matter interaction. Nuc. Inst. Meth. Phys. A 782 (2015): 69-76.

Schmidt R, Wulff J, Zink K. GMctdospp: Description and validation of a CT dose calculation system. Med Phys. 2015 Jul;42(7):4260-70. doi:10.1118/1.4922391. PMID: 26133624

Horst F, Czarnecki D, Zink K. The influence of neutron contamination on dosimetry in external photon beam radiotherapy. Med Phys. 2015 Nov;42(11):6529-36. doi:10.1118/1.4933246. PMID: 26520743.

Iancu G, Kraemer M, Zink K, Durante M, Weber U. Implementation of an efficient Monte Carlo algorithm in TRiP: Physical dose calculation. Int J Part Ther 2 (2015):415-425.

Göpfert F, Schmidt R, Wulff J, Zink K. Effect of ROI filtering in 3D cone-beam rotational angiography on organ dose and effective dose in cerebral investigations. J Appl Clin Med Phys. 2015 Mar 8;16(2):5306. doi:10.1120/jacmp.v16i2.5306. PMID: 26103200.

Ringbæk TP, Brons S, Naumann J, Ackermann B, Horn J, Latzel H, Scheloske S, Galonska M, Bassler N, Zink K, Weber U. Fluence inhomogeneities due to a ripple filter induced Moiré effect. Phys Med Biol. 2015 Feb 7;60(3):N59-69. doi:10.1088/0031-9155/60/3/N59. PMID: 25590354.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow, A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi:10.1016/j.ijrobp.2014.09.039. PMID: 25445556.

Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Staar S, Hegerfeld K, Baues C, Engert A, Eich HAT. Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):46-53. doi:10.1016/j.ijrobp.2015.01.048. PMID: 25863753.

Ammazzalorso F, Jelen U, Engenhart-Cabillic R, Schlegel W. Dosimetric robustness against setup errors in charged particle radiotherapy of skull base tumors. Radiat Oncol. 2014 Dec 5;9:279. doi:10.1186/s13014-014-0279-2. PMID: 25477197.

Witt M, Weber U, Kellner D, Engenhart-Cabillic R, Zink K. Optimization of the stopping-power-ratio to Hounsfield-value calibration curve in proton and heavy ion therapy. Z Med Phys. 2015 Sep;25(3):251-63. doi:10.1016/j.zemedi.2014.11.001. PMID: 25497583.

Ziemann F, Arenz A, Preising S, Wittekindt C, Klussmann JP, Engenhart-Cabillic R, Wittig A. Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation +/- Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am J Cancer Res. 2015 Feb 15;5(3):1017-31. PMID: 26045983.

Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, Hofmann R, Hänze J. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol. 2015 Mar;33(3):110.e19-27. doi:10.1016/j.urolonc.2014.09.016. PMID: 25499923.